Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC). A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Verset, G, Verslype, C, Reynaert, H, Borbath, I, Langlet, P, Vandebroek, A, Peeters, M, Houbiers, G, Francque, S, Arvanitakis, M, Van Laethem, J-L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/
https://www.ncbi.nlm.nih.gov/pubmed/17687341
http://dx.doi.org/10.1038/sj.bjc.6603901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/
https://www.ncbi.nlm.nih.gov/pubmed/17687341
http://dx.doi.org/10.1038/sj.bjc.6603901

Ejemplares similares